Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
49
days
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development
AuthorsKateryna Fedorov; Leo Y. Luo; Alexander G. Bick; Michael R. Savona
Affiliations1. Vanderbilt-Ingram Cancer Center, Nashville, US; 2. Division of Hematology and Oncology, Department of Medicine, Nashville, US; 3. Vanderbilt School of Medicine, Vanderbilt University Medical Center, Nashville, US; 4. Department of Radiation Oncology, Nashville, US; 5. Division of Genetic Medicine, Department of Medicine, Nashville, US
48
days
Targeting RUNX1 Germline Variants: Agents Under Investigation
AuthorsSaman Ghalamkari; Christopher N. Hahn; Amelia Lau; Hamish S. Scott; Claire C. Homan; Anna L. Brown
Affiliations1. Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, Australia; 2. Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia; 3. Adelaide Medical School, The University of Adelaide, Adelaide, Australia
1
days
The Evolving Therapeutic Landscape of Richter Transformation
AuthorsHenry Le; Grace Baek; Ivan Huang; Chloe Siu; Mazyar Shadman
Affiliations1. Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, USA; 2. Department of Pharmacy, University of Washington Medical Center, Seattle, United States; 3. Department of Cellular Immunotherapy, Fred Hutchinson Cancer Center, Seattle, USA; 4. Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, USA
17
days
Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy
AuthorsTala Najdi; Sarah Khanfour; Joe Chalhoub; Shereen Sakkal; Fadi G. Haddad; Hampig Raphael Kourie
Affiliations1. Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut, Lebanon; 2. Saint Joseph University of Beirut, Beirut, Lebanon; 3. Faculty of Medicine, University of Montreal, Quebec, Canada; 4. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
35
days
Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes
AuthorsAzza E. A. Abdalla; Mohammed Abdulgayoom; Abdulrahman F. Al-Mashdali; Firyal Ibrahim; Naseema Gangat; Shehab F. Mohamed
Affiliations1. Internal Medicine Department, Rochester Regional Health, Rochester, USA; 2. Hematology Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; 3. Department of Lab Medicine and Pathology, Hematology Division, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; 4. Division Of Hematology, Mayo Clinic, Rochester, USA
9
days
From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL
AuthorsJessica El-Asmar; John C. Molina; Betty Ky Hamilton
Affiliations1. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA; 2. Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA; 3. Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Cleveland Clinic Cancer Institute, Cleveland, USA
49
days
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies
AuthorsShirley S. Mo; Amy E. DeZern
Affiliations1. Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA
104
days
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications
AuthorsNickolas Steinauer; Mrinal M. Patnaik
Affiliations1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, USA
57
days
Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review
AuthorsKathryn E. Flynn; Lovneet Saini; Aditi Kataria; Kejal Jadhav; Daisy Yang; David Wei
Affiliations1. Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, USA; 2. Novartis Healthcare Pvt. Ltd, Hyderabad, India; 3. Novartis Pharmaceuticals Corporation, East Hanover, USA
49
days
The Role of Inflammation in CMML Pathobiology and Progression
AuthorsNiraj Neupane; Eric Padron
Affiliations1. Moffitt Cancer Center, Tampa, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days